Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 4

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 4
---
 IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in “CER”. For additional information on CER %, see “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.

#### Revenue
Revenue for the fiscal year ended March 31, 2025 was JPY 4,581.6 billion (JPY +317.8 billion and +7.5% AER, +2.9% CER). The increase is attributable to favorable foreign exchange rates and growth from business momentum of Gastroenterology (“GI”), Rare Diseases, Plasma-Derived Therapies (“PDT”), Oncology and Vaccines. Among our six key business areas, the increase of these business areas was offset in part by a decrease in Neuroscience. The decrease in Neuroscience, which was partially mitigated by favorable foreign exchange rates, was largely attributable to continued generic erosion of sales of VYVANSE (for attention deficit hyperactivity disorder (“ADHD”)) in the U.S., which began following loss of exclusivity in August 2023. In addition, revenue outside of our six key business areas decreased mainly due to the decline in sales of AZILVA (for hypertension), which were JPY 11.8 billion (JPY -21.8 billion and -64.9% AER, -64.9% CER) following the entry of generic competitors in Japan beginning in June 2023.

<div align='center'>2</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

#### Revenue by Geographic Region
The following shows revenue by geographic region:

|                                | Revenue: | For the fiscal year ended 
 March 31,                 |    2024 |     |     |    2025 |     |     | Amount of Change | AER |       |     |     | % Change |      |   |     | % Change | CER |      | Billion JPY or percentage |
|:-------------------------------|:---------|:--------------------------|--------:|:----|:----|--------:|:----|:----|:-----------------|:----|------:|:----|:----|:---------|-----:|:--|:----|:---------|:----